Clinical Trial

Triple-Blind Randomized Clinical Trial of Tocilizumab vs Placebo: Potential Use of an IL-6 Antagonist as an Adjuvant to Standard Treatment for Treatment-Resistant Major Depression in the Brazilian Public Health System (SUS)

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Clinical trial aimed at evaluating whether a single infusion of tocilizumab, a medication that blocks the action of an inflammatory molecule called interleukin-6 (IL-6), can reduce symptoms of treatment-resistant major depression compared to placebo in non-hospitalized patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-26.
Trial Details
NCT Number NCT07052058
Lead Sponsor Hospital de Clinicas de Porto Alegre
Conditions Treatment-Resistant Major Depressive Disorder
Enrollment 32 participants
Start Date 2026-07-01
Primary Completion 2028-07-01 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-15